Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2

Expert Opinion on Therapeutic Patents

Volumn 27, Issue 2, 2017, Pages 145-161

  Kettle, Jason G ^a   Åstrand, Annika ^b   Catley, Matthew ^b   Grimster, Neil P ^a   Nilsson, Magnus ^b   Su, Qibin ^a   Woessner, Richard ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

JAK; JAK1 inhibitor; JAK2 inhibitor; JAK3 inhibitor; Janus kinase inhibitors; myelofibrosis; oncology; rheumatoid arthritis; ruxolitinib; tofacitinib; TYK2 inhibitor

Indexed keywords

RUXOLITINIB; TOFACITINIB; JANUS KINASE; PROTEIN KINASE INHIBITOR;

ASTHMA; AUTOIMMUNITY; CELL SURVIVAL; CYTOKINE PRODUCTION; DERMATOPHAGOIDES; ENZYME ACTIVITY; ENZYME INHIBITION; EOSINOPHIL; GENE REARRANGEMENT; HUMAN; IC50; INFLAMMATORY CELL; MEDICAL HISTORY; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; PHARMACOPHORE; POLYCYTHEMIA VERA; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT ALLERGY; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; DOSE RESPONSE; DRUG DESIGN; ENZYMOLOGY; PATENT;

ANIMALS; ASTHMA; AUTOIMMUNE DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; JANUS KINASES; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS;

EID: 85009250620     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1080/13543776.2017.1252754     Document Type: Review

References (102)

1. Kettle JG, Åstrand A, Catley M, et al. Inhibitors of JAK-family kinases:an update on the patent literature 2013–2015, part 1. Expert Opin Ther Pat. 2016. doi:10.1080/13543776.2017.1252753.
2. Durham AL, Caramori G, Chung KF, et al. Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease. Transl Res. 2016;167:192–203.
3. Lloyd CM, Saglani S., Epithelial cytokines and pulmonary allergic inflammation. Curr Opin Immunol. 2015;34:52–58.
4. 2 agonist:a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016 Apr 26. doi:10.1016/S0140-6736(16)30307-5. [Epub ahead of print].
5. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455–2466.
6. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088–1098.• First demonstration that a blood biomarker can predict response to anti-IL-13 therapies.
7. Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma:pooled data from two randomised placebo-controlled studies. Thorax. 2015;70:748–756.
8. Brightling CE, Chanez P, Leigh R, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma:a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015;3:692–701.
9. Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma:a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2:879–890.
10. Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds:a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016 May 10. doi:10.1016/S2213-2600(16)30031-5. [Epub ahead of print].
11. Gauvreau GM, O’Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370:2102–2110.
12. Hart TK, Blackburn MN, Brigham-Burke M, et al. Preclinical efficacy and safety of pascolizumab (SB 240683):a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol. 2002;130:93–100.
13. O’Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway:impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311–328.• Recent comprehensive review of JAK/STAT biology and leading inhibitors in development.
14. Jiang H, Harris MB, Rothman P. IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol. 2000;105:1063–1070.
15. Pazdrak K, Stafford S, Alam R. The activation of the Jak-STAT 1 signaling pathway by IL-5 in eosinophils. J Immunol. 1995;155:397–402.
16. Zhong J, Sharma J, Raju R, et al. TSLP signaling pathway map:a platform for analysis of TSLP-mediated signaling. Database (Oxford). 2014 Feb 25.
17. Rincon M, Irvin CG. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci. 2012;8:1281–1290.
18. Dalby R, Suman J. Inhalation therapy:technological milestones in asthma treatment. Adv Drug Deliv Rev. 2003;55:779–791.
19. Wark PA, Johnston SL, Bucchieri F, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005;201:937–947.• First indication that asthmatics may have defective type I interferon response to viruses.
20. Forbes RL, Gibson PG, Murphy VE, et al. Impaired type I and III interferon response to rhinovirus infection during pregnancy and asthma. Thorax. 2012;67:209–214.
21. Contoli M, Message SD, Laza-Stanca V, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med. 2006;12:1023–1026.
22. Raundhal M, Morse C, Khare A, et al. High IFN-γ and low SLPI mark severe asthma in mice and humans. J Clin Invest. 2015;125:3037–3050.
23. Chambers ES, Nanzer AM, Pfeffer PE, et al. Distinct endotypes of steroid-resistant asthma characterized by IL-17A(high) and IFN-γ(high) immunophenotypes:potential benefits of calcitriol. J Allergy Clin Immunol. 2015;136:628–637.
24. Sykes A, Macintyre J, Edwards MR, et al. Rhinovirus-induced interferon production is not deficient in well controlled asthma. Thorax. 2014;69:240–246.
25. Kudlacz E, Conklyn M, Andresen C, et al. The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur J Pharmacol. 2008;582:154–161.
26. Wiegman CH, Russell KE, Seiffert J, et al. The selective pan-Janus kinase (JAK) inhibitor VR588 demonstrates potent anti-inflammatory activity in a murine chronic house dust mite (HDM) model of asthma. C34. New Basic Sci Asthma Aller Inflam I. 2015 May 1;185:A6435–A6435.
27. Ashino S, Takeda K, Pine PR, et al. Janus kinase (JAK) 3 inhibitor, R256, attenuates allergen-induced airway hyperresponsiveness and airway inflammation in mice. B33. Asthma Ther. 2012;1:A2766–A2766.
28. Montes A, Perez-Pampin E, Navarro-Sarabia F, et al. Rhematoid arthritis response to treatment across IgG1 allotype–anti-TNF incompatibility:a case-only study. Arthritis Res Ther. 2015;17:63.
29. O’Shea JJ, Kontzias A, Yamaoka K, et al. Ann Rheum Dis. 2013;72:ii111–ii115.
30. Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25–36.• Recent review on receptor dependency of the different JAK isoforms.
31. Rönnblom L, Eloranta M-L. The interferon signature in autoimmune diseases. Curr Opin Rheumatol. 2013;25:248–253.
32. Pollard KM, Cauvi DM, Toomey CB, et al. Interferon-γ and systemic autoimmunity. Discov Med. 2013;16:123–131.
33. Thoma G, Drückes P, Zerwes H-G. Selective inhibitors of the Janus kinase Jak3–are they effective? Bioorg Med Chem Lett. 2014;24:4617–4621.
34. Haan C, Rolvering C, Raulf F, et al. JAK1 has a dominant role over JAK3 in signal transduction through gc-containing cytokine receptors. Chem Biol. 2011;18:314–323.
35. Sakaguchi S, Ono M, Setoguchi R, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 2006;212:8–27.
36. Jiangsu Kefeiping Medicine Co Ltd. 4-Substituted pyrrolo[2,3-d]pyrimidine compound and use thereof. WO2015110092; 2015
37. Jiangsu Hengrui Medicine Co Ltd. Shanghai Hengrui Pharmaceutical Co Ltd. Pyrrole six-membered heteroaryl ring derivative, preparation method therefor, and medicinal uses thereof. WO2013091539. 2013.
38. Ligand Pharmaceuticals Inc. Janus kinase inhibitor compounds and methods. WO2013025628. 2012.
39. Merck Sharp & Dohme Corp. Acyclic cyanoethylpyrazolo pyridones as Janus kinase inhibitors. WO2014146493. 2014.
40. Merck Sharp & Dohme Corp. N-(2-Cyano heterocyclyl)pyrazolo pyridones as Janus kinase inhibitors. WO2014146492. 2014.
41. Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides as Janus kinase inhibitors. WO2013040863. 2013.
42. Merck Sharp & Dohme Corp. Pyrrolopyrimidines as Janus kinase inhibitors. WO2013085802. 2013.
43. Merck Sharp & Dohme Corp. Azaindoles as Janus kinase inhibitors. WO2013052355. 2013.
44. Nerviano Medical Sciences Srl. Substituted pyrroles active as kinases inhibitors. WO2014019908. 2014.
45. Nerviano Medical Sciences Srl. Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors. WO2013014039. 2013.
46. Brasca MG, Gnocchi P, Nesi M, et al. Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders. Bioorg Med Chem Lett. 2015;23:2387–2407.
47. Nimbus Lakshmi Inc. TYK2 inhibitors and uses thereof. WO2015131080. 2015.
48. Nissan Chemical Industries Ltd. Tricyclic heterocyclic compounds and JAK inhibitors. WO2013024895. 2012.
49. Nissan Chemical Industries Ltd. Tricyclic pyrrolopyridine compound, and JAK inhibitor. WO2014123167. 2014.
50. Novartis Tiergesundheit Ag. New compounds. WO2015144773. 2015.
51. Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds. WO2011075334. 2011.
52. F Hoffmann-La Roche AG. Fused tricyclic compounds for use as inhibitors of Janus kinases. WO2013007765. 2012.
53. Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of Janus-related kinases (JAK). WO2014128591. 2014.
54. Kaila N, Vazquez M, Unwalla R, et al. Identification of selective JAK1 inhibitors for treatment of autoimmune diseases. MEDI 24, 251st ACS National Meeting, San Diego, CA; 2016 Mar 13–17; Spring Meeting.
55. Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines. WO2015173683. 2015.
56. Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides. WO2015083028. 2015.
57. Principia Biopharma Inc. Azaindole derivatives as tyrosine kinase inhibitors. WO2012158785. 2012.
58. Principia Biopharma Inc. Azaindole derivatives as JAK-3 inhibitors. WO2014081732. 2014.
59. Smyth LA, Collins I. Measuring and interpreting the selectivity of protein kinase inhibitors. J Chem Biol. 2009;2:131–151.
60. Portola Pharmaceuticals Inc. Bicyclic dihydropyridone kinase inhibitors. WO2014051653. 2014.
61. Portola Pharmaceuticals Inc. Bicyclic oxa-lactam kinase inhibitors. WO2014051654. 2014.
62. Portola Pharmaceuticals Inc. Substituted pyrimidinyl kinase inhibitors. WO2014058921. 2014.
63. Portola Pharmaceuticals Inc. Pyridazine compounds as JAK inhibitors. WO2015123453. 2015.
64. Principia Biopharma Inc. Azaindole derivatives as JAK-3 inhibitors. WO2014081732. 2014.
65. F Hoffmann-La Roche AG. Fused tricyclic compounds for use as inhibitors of Janus kinases. WO2013007765. 2013.
66. F Hoffmann-La Roche AG. Tricyclic heterocyclic compounds, compositions and methods of use thereof as JAK inhibitors. WO2013007768. 2013.
67. F Hoffmann-La Roche AG. Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors. WO2013030138. 2013.
68. Padilla F, Bhagirath N, Chen S, et al. Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors. J Med Chem. 2013;56:1677–1692.
69. F Hoffmann-La Roche AG. Genentech Inc. Triazolopyridine compounds, compositions and methods of use thereof. WO2015032286. 2015.
70. F Hoffmann-La Roche AG. Genentech Inc. Thiazolopyridine compounds, compositions and their use as TYK2 kinase inhibitors. WO2015091584. 2015.
71. F Hoffmann-La Roche AG. Genentech Inc. Imidazopyridine compounds, compositions and methods of use. WO2013041539. 2012.
72. F Hoffmann-La Roche AG. Genentech Inc. 5-Chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors. WO2015177326. 2015.
73. Genentech Inc. Pyrazolopyrimidine JAK inhibitor compounds and methods. WO2011003065. 2011.
74. F Hoffmann-La Roche AG. Pyrazolo[1,5a]pyrimidine and thieno[3,2b]pyrimidine derivatives as IRAK4 modulators. WO2012007375. 2012.
75. Sareum Holdings plc. Pharmaceutical compounds. WO2015032423. 2015.
76. Sareum Ltd. Oxazole tyrosine kinase inhibitors. WO2008139161. 2008.
77. Sareum Ltd. Pharmaceutical compounds. WO2010055304. 2010.
78. Shanghai Haihe Pharmaceutical Co., Ltd., Shanghai Institute of Materia Medica, Chinese Academy of Sciences. WO2015188681. 2015.
79. China Gateway Technology Development (Shanghai) Co Ltd., Shanghai Yunyi Healthcare Management Co Ltd. Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof. WO2014111037. 2014.
80. Incyte Corporation. Azetidine and cyclobutane derivatives as JAK inhibitors. WO2009114512. 2009.
81. Shanghai Yunyi Healthcare Management Co., Ltd. Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof. WO2013152717. 2013.
82. Beijing Hanmi Pharmaceutical Co Ltd. Compound inhibiting kinase activities of BTK and/or JAK3. WO2015039612. 2015.
83. Incyte Corp. JAK1 inhibitors for the treatment of myelodysplastic syndromes. WO2015131031. 2015.
84. Taiho Pharmaceutical Co Ltd. Azaindole derivative. WO2015119126. 2015.
85. Takeda Pharmaceutical Co Ltd. Heterocyclic compound. WO2014157569. 2014.
86. Takeda Pharmaceutical Co Ltd. Heterocyclic compound. WO2013125543. 2013.
87. Takeda Pharmaceutical Co Ltd. Heterocyclic compound. WO2013180265. 2013.
88. Takeda Pharmaceutical Co Ltd. Heterocyclic compound. WO2015016206; 2015.
89. Takeda Pharmaceutical Co Ltd. Heterocyclic compound. WO2013146963. 2013.
90. Tolero Pharmaceuticals Inc. JAK2 and ALK2 inhibitors and methods for their use. WO2014151871. 2014.
91. Supergen Inc. Pyrimidine-2,4-diamine derivatives and their use as jak2 kinase inhibitors. WO2008106635. 2008.
92. Goldberg FW, Ward RA, Powell SJ, et al. Rapid generation of a high quality lead for transforming growth factor-β (TGF-β) type I receptor (ALK5). J Med Chem. 2009;52:7901–7905.
93. Farmer LJ, Ledeboer MW, Hoock T, et al. Discovery of VX-509 (decernotinib):a potent and selective Janus kinase 3 inhibitor for the treatment of autoimmune diseases. J Med Chem. 2015;58:7195–7216.
94. Vertex Pharmaceuticals Inc. Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor. WO2013070606. 2013.
95. Vertex Pharmaceuticals Inc. Processes and intermediates for producing azaindoles. WO2013006634. 2013.
96. Vertex Pharmaceuticals Inc. Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor. WO2014074471. 2014.
97. Vertex Pharmaceuticals Inc. Pharmaceutical combinations useful for treating rheumatoid arthritis. WO2014201332. 2014.
98. Vertex Pharmaceuticals Inc. Solid forms of a JAK inhibitor. WO2014110259. 2014.
99. Vertex Pharmaceuticals Inc. Isotopically enriched azaindoles. WO2015027005. 2015.
100. YM BioSciences Inc. Phenyl amino pyrimidine bicyclic compounds and uses thereof. WO2014000032. 2014.
101. DTRM Biopharma Co Ltd. Isoxazole derivative that inhibits activity of Janus kinases (JAKs). WO2014101295. 2014.
102. Dell CP. Antiproliferative naphthopyrans:biological activity, mechanistic studies and therapeutic potential. Curr Med Chem. 1998;5:179–194.